Beremagene geperpavec · Vyjuvek
Gene therapy / editing
Evidence outlook
Approved: Dystrophic Epidermolysis Bullosa
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
Also approved (3)
- Wounds in patients with dystrophic epidermolysis bullosa
- Dystrophic epidermolysis bullosa (wounds), from birth
- Wounds in patients with dystrophic epidermolysis bullosa with COL7A1 mutations, from birth
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
GEM-3 NCT04491604 · Dystrophic Epidermolysis Bullosa The trial used within-person randomization, quadruple blinding, and a matching placebo, and its primary endpoint was the clinically meaningful measure of complete wound closure. The primary comparison was met (20.9 versus 6.7 healed wounds; p=0.00192), but the study was small, including only 31 participants, so the evidence is limited despite the favorable result. Registry: NCT04491604 | 3 | Primary Wound With Complete Wound Healing (100% Wound Closure) on Weeks 22 and 24 or Weeks 24 and 26 (26 weeks post-baseline) 2021-10-29 | Primary Wound With Complete Wound Healing (100% Wound Closure) on Weeks 22 and 24 or Weeks 24 and 26 (26 weeks post-baseline): B-VEC 20.9 number of wounds with complete healing | Placebo 6.7 number of wounds with complete healing | Partial signal | link ↗ |
View 1 more trial
B-VEC NCT04917874 · Dystrophic Epidermolysis Bullosa Registry: NCT04917874 | 3 | To record safety outcomes of participants while on B-VEC. (Up to 112 weeks) 2023-07-31 | 74.5% (35 subjects) had at least one adverse event, mostly mild or moderate; 17 serious events in 14 subjects, none treatment related. | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (2)
What this study did
What this study did
Phase 1/2 (1)
What this study did
Competitive landscape
This drug's own stage for Dystrophic Epidermolysis Bullosa: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Beremagene Geperpavec (Vyjuvek): this drug | Approved | Gene therapy / editing | COL7A1 (type VII collagen gene replacement) | Partial signal | NCT04491604: Primary Wound With Complete Wound Healing (100% Wound Closure) on Weeks 22 and 24 or Weeks 24 and 26 (26 weeks post-baseline): B-VEC 20.9 number of wounds with complete healing | Placebo 6.7 number of wounds with complete healing | |
| ALLO-ASC | Phase 2 | Cell therapy | Adipose-derived MSC therapy | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent